The role of biologically effective dose (BED) in clinical oncology.
Jones B, Dale RG, Deehan C, Hopkins KI, Morgan DA.
Clin Oncol (R Coll Radiol). 2001;13(2):71-81. doi: 10.1053/clon.2001.9221.
The radiobiology of hypofractionation.
Nahum AE.
Clin Oncol (R Coll Radiol). 2015 May;27(5):260-9. doi: 10.1016/j.clon.2015.02.001. Epub 2015 Mar 18.
Breast cancer radiobiology: The renaissance of whole breast radiation fractionation (Review).
Alzibdeh A, Abuhijlih R, Abuhijla F.
Mol Clin Oncol. 2024 Oct 22;21(6):97. doi: 10.3892/mco.2024.2795. eCollection 2024 Dec.
Challenges in radiobiology - technology duality as a key for a risk-free alpha/beta ratio.
Bouleftour W, Guy JB, Moreno-Acosta P, Rodriguez Lafrasse C, Sargos P, Magné N.
Bull Cancer. 2023 Jul-Aug;110(7-8):768-775. doi: 10.1016/j.bulcan.2023.02.006. Epub 2023 Mar 3.
[Alpha/beta ratio revisited in the era of hypofractionation].
Hennequin C, Dubray B.
Cancer Radiother. 2013 Oct;17(5-6):344-8. doi: 10.1016/j.canrad.2013.06.035. Epub 2013 Aug 22.
[Which alpha/beta ratio for prostate cancer in 2019?].
Cosset JM, Chargari C, Créhange G.
Cancer Radiother. 2019 Jul;23(4):342-345. doi: 10.1016/j.canrad.2019.01.004. Epub 2019 May 20.
Cellular Radiosensitivity of Soft Tissue Sarcoma.
Haas RL, Floot BGJ, Scholten AN, van der Graaf WTA, van Houdt W, Schrage Y, van de Ven M, Bovée JVMG, van Coevorden F, Vens C.
Radiat Res. 2021 Jul 1;196(1):23-30. doi: 10.1667/RADE-20-00226.1.
Radiation biology of malignant melanoma.
Rofstad EK.
Acta Radiol Oncol. 1986 Jan-Feb;25(1):1-10. doi: 10.3109/02841868609136368.
Hypofractionation for prostate cancer: a critical review.
Miles EF, Lee WR.
Semin Radiat Oncol. 2008 Jan;18(1):41-7. doi: 10.1016/j.semradonc.2007.09.006.
Depression diagnosis based on electroencephalography power ratios.
Chang J, Choi Y.
Brain Behav. 2023 Aug;13(8):e3173. doi: 10.1002/brb3.3173. Epub 2023 Jul 21.
